Hosted on MSN7h
Citigroup Initiates Coverage of Candel Therapeutics (CADL) with Buy Recommendation
Fintel reports that on February 20, 2025, Citigroup initiated coverage of Candel Therapeutics (NasdaqGM:CADL) with a Buy ...
Seeking Alpha13d
Candel initiated at buy by Citi, lead immunotherapy drugs cited
BofA believes Candel (NASDAQ:CADL) could have peak sales of $2.9B by 2029. It noted that its cash runway of $103M should be able to take it into Q1 2027, which would support not only this year's ...
Business Insider13d
Candel Therapeutics initiated with a Buy at BofA
BofA initiated coverage of Candel Therapeutics (CADL) with a Buy rating and $15 price target Candel’s pipeline includes two lead drugs – CAN-2409 and CAN-3110 – both of which have shown ...